Benutzer: Gast  Login
Dokumenttyp:
journal article 
Autor(en):
Hochhaus, A; O'Brien, SG; Guilhot, F; Druker, BJ; Branford, S; Foroni, L; Goldman, JM; Müller, MC; Radich, JP; Rudoltz, M; Mone, M; Gathmann, I; Hughes, TP; Larson, RA; IRIS Investigators 
Titel:
Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. 
Abstract:
Imatinib mesylate is considered standard of care for first-line treatment of chronic phase chronic myeloid leukemia (CML-CP). In the phase III, randomized, open-label International Randomized Study of Interferon vs STI571 (IRIS) trial, previously untreated CML-CP patients were randomized to imatinib (n=553) or interferon-alpha (IFN) plus cytarabine (n=553). This 6-year update focuses on patients randomized to receive imatinib as first-line therapy for newly diagnosed CML-CP. During the sixth yea...    »
 
Zeitschriftentitel:
Leukemia 
Jahr:
2009 
Band / Volume:
23 
Heft / Issue:
Seitenangaben Beitrag:
1054-61 
Sprache:
eng 
Print-ISSN:
0887-6924 
TUM Einrichtung:
III. Medizinische Klinik und Poliklinik